Case Report Open Access

Osimertinib Induced Interstitial Lung Disease A Case Report and Management with Literature Review

Abstract

Interstitial Lung Disease (ILD) is an uncommon side effect of osimertinib, an oral Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) approved for front line therapy in stage IV and adjuvant usage in stage II -III resected adenocarcinoma of the lung. We present a case of Osimertinib induced ILD in a 77 year old man with metastatic adenocarcinoma of the lung who tolerated Osimertinib rechallenge well and continued to take it for almost a year. This case study emphasizes the importance of careful Osimertinib rechallenge in a subset of patients.

Nishith Vaddeboina*, Namratha Sai Reddy, Nirni SS

To read the full article Download Full Article | Visit Full Article